Dupixent® (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis

Nearly three times as many dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo there are currently no approved medicines specifically indicated to treat prurigo nodularis;  regulatory submissions for dupixent are under priority review in the u.s. and under review in the european union 22 dupixent abstracts are being presented at the eadv 2022 congress across four dermatological diseases with underlying type 2 inflammation tarrytown, n.y. and paris , sept.
REGN Ratings Summary
REGN Quant Ranking